Once considered almost inevitable, the passage of BIOSECURE – the US legislation aiming at limiting the involvement of Chinese contract development and manufacturing firms in the biotech industry – now seems in a bit of doubt.
Several factors have caused the once-blazing legislation to stumble. BIOSECURE failed to hitch a ride on the House version of...








